Research from our State of Employee Benefits report has shown that the usage of GLP-1 medications such as Ozempic® and Wegovy® has increased since 2022. These medications were first approved for Type 2 diabetes (T2D) but the scope of users has expanded to patients with no diabetes diagnosis, who may be using them to manage their weight.
As the population of GLP-1 users grows, so does the cost of these medications. GLP-1 users are found within each generation of the workforce, and the cost increases are impacting both employers and their employees. Employers are increasing their total Rx spend on these medications, and the cost itself is growing. Plus, the overall healthcare costs are higher for GLP-1 users.
It’s important to consider how to address these healthcare trends as an organization. Employers that find ways to manage the costs of GLP-1 medications may help reduce future health care costs. One suggestion is to develop a GLP-1 cost management strategy that combines different activities, including data analysis, goal setting and control implementation that help drive change among covered employees.
This report provides a starting point to build your own strategy that manages costs and provides employees with the support they need for optimal care. Download now and discover how GLP-1 usage is impacting employers’ healthcare budgets and learn key insights, such as:
- GLP-1 usage by demographic
- Increased Rx spend on GLP-1 medications
- Tips to mitigate costs and risks of GLP-1 usage
- And more!
Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S.
The information provided does not, and is not intended to, constitute legal advice; instead, all information and content herein is provided for general informational purposes only and may not constitute the most up-to-date legal or other information. Benefitfocus does not act in a fiduciary capacity in providing products or services; any such fiduciary capacity is explicitly disclaimed.
CN4624887_0727
